Vivimed Labs’ JV to launch Ranitidine OTC tables in US markets

26 Feb 2018 Evaluate

Vivimed Labs’ Joint Venture (JV) has received its first product approval Ranitidine tablet USP, 150 mg (OTC) and will be launched in the US markets. As per the IRI data, the US OTC market for Ranitidine tablets, which is a generic form of the popular brand is Zantac, is around $200 million.

The product will be manufactured at JV's oral dosage manufacturing facility in Chennai. The product will be launched in the US markets immediately. Ranitidine belongs to a class of drugs known as H2 histamine blockers. It is used to treat peptic ulcers of the stomach and intestines and gastroesophageal reflux and heartburn related to indigestion.

Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.


Vivimed Labs Share Price

16.75 -0.88 (-4.99%)
01-Jan-2026 14:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1718.85
Dr. Reddys Lab 1250.30
Cipla 1499.60
Zydus Lifesciences 913.35
Lupin 2101.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×